Lab-Grown tumor 'Vessels' could predict who responds to immunotherapy

NCT ID NCT07343596

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study aims to see if a custom-made tumor culture system can predict how oral cavity cancer responds to the immunotherapy drug pembrolizumab before surgery. Twenty participants will provide a biopsy, receive pembrolizumab as standard care, and then have their tumor analyzed. Researchers will check if the lab model's predictions match the actual tumor response, with the goal of identifying biomarkers for personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab
What this could lead to: If successful, this could lead to a personalized test that predicts which oral cancer patients will benefit from immunotherapy before surgery.
What could go wrong: This is a very small, early-stage study (20 participants) focused on lab measurements, not treatment outcomes. The model may not reliably predict real-world responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL CAVITY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mouth Neoplasms oral cavity cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORAL CAVITY CANCER

Contacts and locations

Locations

University of Wisconsin - Madison
RECRUITING

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.